Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List

David M Sayah; Joseph M Pilewski

doi:10.1016/j.thorsurg.2022.01.002

Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List

Thorac Surg Clin. 2022 May;32(2):111-119. doi: 10.1016/j.thorsurg.2022.01.002.

Authors

David M Sayah¹, Joseph M Pilewski²

Affiliations

¹ Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, 10833 Le Conte Avenue, Box 951690, Los Angeles, CA 90095-1690, USA. Electronic address: dsayah@mednet.ucla.edu.
² Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, NW 628 MUH, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.

PMID: 35512930
DOI: 10.1016/j.thorsurg.2022.01.002

Abstract

The medical care of patients awaiting lung transplantation is complex and requires the treatment of active medical conditions, including lung disease, while at the same time maintaining candidacy for transplantation. Some medications that would otherwise be considered routine may create undesirable challenges or complications in the perioperative setting. Therefore, a comprehensive assessment of the risks and benefits of these medications must take into account both their potential utility in managing a patient's current disease state, as well as the risks of compromising postlung transplant outcomes. In this review, we summarize the available data regarding several medications that are commonly used to treat patients with a variety of lung diseases, but that may impact a patient's course on the waiting list or in the posttransplant period.

Keywords: Antifibrotics; Corticosteroids; Glucocorticoids; Lung transplantation; Nintedanib; Pirfenidone; Sirolimus; mTOR inhibitors.

Publication types

Review

MeSH terms

Humans
Lung Transplantation*
Outpatients
Waiting Lists*